+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 80Years
All Genders
ID06902740

Evaluating PCSK9 Inhibitor with Statin Treatment for Adults Aged 18 to 80 with Asymptomatic Intracranial Artery Narrowing to Reduce Stroke Risk

Led by Peking Union Medical College Hospital · Updated on 2026-06-12

300

Participants Needed

19

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying asymptomatic intracranial atherosclerosis ICAS, a condition where arteries in the brain narrow without causing symptoms but increase the risk of stroke and cognitive decline. This trial evaluates the effects and safety of combining a PCSK9 inhibitor drug with statin therapy compared to statin therapy alone in reversing this artery narrowing. The study is a multicenter, open-label, randomized controlled trial with blinded assessment of results. Participants will be randomly assigned to one of two groups one receiving Recaticimab a PCSK9 inhibitor every 12 weeks alongside daily statin medication rosuvastatin or atorvastatin, and the other receiving statin therapy alone. Ezetimibe may be added based on cholesterol levels. Treatments last for 24 weeks. Recaticimab is designed with a modification to extend its activity, allowing dosing every 12 weeks. The primary goal is to measure changes in artery plaque using high-resolution MRI. During the study, participants will undergo MRI scans to assess plaque changes, blood tests to measure cholesterol and brain injury markers, and clinical evaluations for stroke or transient ischemic attacks. Additional outcomes include cardiovascular events and cholesterol management success. After the 24-week treatment, participants will be followed for over a year via clinical or phone visits to monitor long-term effects. The study aims to enroll 300 participants and includes safety monitoring by an independent board.

CONDITIONS

Brief Title

PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis

Research Team

W

Weihai Xu, MD

Y

Yiyang Liu, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here